Inotek Pharmaceuticals

About:

Inotek Pharmaceuticals develops drug candidates to address significant diseases of the eye.

Top Investors: Horizon Technology Finance, Caisse de Depot et Placement du Quebec, Pitango VC, Rho Capital Partners, Rho Ventures

Description:

Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.

Total Funding Amount:

$126M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Lexington, Massachusetts, United States

Founded Date:

1996-01-01

Contact Email:

info(AT)inotekcorp.com

Founders:

Andrew Salzman

Number of Employees:

11-50

Last Funding Date:

2013-09-27

IPO Status:

Delisted

Industries: